K2 - Cell Line (ID:51100)
| HMS LINCS ID: | 51100 |
| Name: | K2 |
| Alternative Names: | |
| LINCS ID: | LCL-2091 |
| Alternative ID: | CLO_0037127 |
| Parent Cell Line: | |
| Reference Source: | Hensin Tsao (Masschusetts General Hospital) |
| Organism: | Homo sapiens |
| Organ: | skin |
| Tissue: | |
| Cell Type: | |
| Details of Cell Type: | |
| Donor Sex: | |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | DOID:1909, malignant melanoma |
| Details of Disease: | |
| Production Details: | |
| Genetic Modification(s): | |
| Known Mutations: | |
| Citation Information for Mutations: | COSS1298160 |
| Verification Reference Profile: | |
| Growth Properties: | |
| Recommended Culture Conditions: | |
| Relevant Citations: | |
| Usage Note: | |
| Comments: | |
| Date Publicly Available: | 2015-01-10 |
| Most Recent Update: | 2016-07-12 |
Batch Information for HMSL51100-2:
| HMS LINCS Batch ID: | 51100-2 |
| Provider: | Nathan Moerke (Harvard Medical School) |
| Provider Catalog ID: | |
| Provider Batch ID: | |
| Source Information: | Obtained by Nathan Moerke (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes) and distributed to Mohammad Fallahi-Sichani in 2012. CMT previously had obtained the cells from Hensin Tsao (Massachusetts General Hospital). |
| Date Received: | 2012 |
| HMS QC Outcome: | AMBIGUOUS |
| Transient Modification(s): | |
| Comments: | |
| Date Publicly Available: | 2016-06-06 |
| Most Recent Update: | 2016-09-09 |
HMS QC Testing Events for HMSL51100-2:
| Date | HMS QC Outcome | Comment | Files |
|---|---|---|---|
| 08/05/2013 | AMBIGUOUS | 003399_K2_Report.pdf |